Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 13/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966619 | 0.89 | SMN1; SMN2 (0.44) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL5689073 | 0.87 | SMN1; SMN2 (0.46) | CXCR4MEN1CHRM2KMT2ASMN1; SMN2 | |
| SCHEMBL11066505 | 0.85 | MEN1 (0.40) | CXCR4MEN1CHRM2KMT2AHRH3 | |
| SCHEMBL9066655 | 0.82 | SMN1; SMN2 (0.42) | CXCR4MEN1KMT2ASMN1; SMN2CHRM5 | |
| SCHEMBL673985 | 0.80 | CXCR4 (0.47) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL28888023 | 0.79 | CXCR4 (0.53) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL674208 | 0.78 | CXCR4 (0.45) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL22996225 | 0.77 | CXCR4 (0.50) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL9829105 | 0.77 | CXCR4 (0.50) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL2550467 | 0.77 | MEN1 (0.44) | MEN1CHRM2ADRA2CKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161859-A1 | USE OF CXCR4 ANTAGONISTS | University of Washington Center for Commercialization | 2021-06-03 | — | — | US | claimed |
| US-20150030561-A1 | Use of CXCR4 Antagonists | GENZYME CORP. (US) | 2015-01-29 | — | — | US | claimed |
| EP-2709991-A1 | USE OF CXCR4 ANTAGONISTS | Genzyme Corporation (US) | 2014-03-26 | — | — | EP | claimed |
| WO-2012158707-A1 | USE OF CXCR4 ANTAGONISTS | GENZYME CORPORATION (US) | 2012-11-22 | — | — | WO | claimed |
| US-20110280827-A1 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | HU YANPING (US) | 2011-11-17 | — | — | US | claimed |
| US-20110281814-A1 | METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER | GENZYME CORPORATION | 2011-11-17 | — | — | US | claimed |
| EP-2371361-A1 | Methods to mobilize progenitor/stem cells | Genzyme Global S.à.r.l. (LU) | 2011-10-05 | — | — | EP | claimed |
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORPORATION | 2010-02-11 | — | — | US | claimed |
| WO-2007047882-A2 | COMBINATION OF CXCR4 ANTAGONIST AND MORPHOGEN TO INCREASE ANGIOGENESIS | CARITAS ST. ELIZABETH MEDICAL CENTER OF BOSTON, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-20060194776-A1 | Compositions and methods for treating tissue ischemia | CARITAS ST. ELIZABETH MEDICAL CENTER OF BOSTON, INC. (US) | 2006-08-31 | — | — | US | claimed |
| EP-1148875-B1 | METHODS AND COMPOSITIONS TO ENHANCE WHITE BLOOD CELL COUNT | ANORMED INC (CA) | 2004-06-09 | — | — | EP | claimed |
| US-6670354-B2 | Administering cyclic polyamine compound to elevate white blood cell (WBC) count | ANORMED, INC. | 2003-12-30 | — | — | US | claimed |
| US-20020058653-A1 | Methods to enhance white blood cell count | ANORMED, INC. (CA) | 2002-05-16 | — | — | US | claimed |
| US-6365583-B1 | ADMINISTERING NITROGEN CONTAINING CYCLIC COMPOUNDS FOR THERAPY OF ENHANCING WHITE BLOOD CELL COUNT | ANORMED, INC. | 2002-04-02 | — | — | US | claimed |
| EP-1148875-A1 | METHODS AND COMPOSITIONS TO ENHANCE WHITE BLOOD CELL COUNT | ANORMED INC. (CA) | 2001-10-31 | — | — | EP | claimed |
| WO-2000045814-A1 | METHODS AND COMPOSITIONS TO ENHANCE WHITE BLOOD CELL COUNT | ANORMED INC. (CA) | 2000-08-10 | — | — | WO | claimed |
| US-6001826-A | CONTAINING TWO TETRAAZACYCLOHEXADECANE, PENTAAZACYCLOHEAXDECANE, OR TETRAAZACYCLOTETRADECANE RINGS; ACTIVE AGAINST HIV-INFECTED CELLS | ANORMED, INC. (CA) | 1999-12-14 | — | — | US | claimed |
| WO-2025230907-A1 | A CXCR4 ANTAGONIST, A STATS ACTIVATOR, AND/OR AN AGENT THAT INCREASES NITRIC OXIDE CONTENT FOR USE IN METHODS OF IMPROVING NERVE REGENERATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-06 | — | — | WO | disclosed |
| US-5021409-A | Antiviral cyclic polyamines | JOHNSON MATTHEY PLC (GB) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161859-A1 | USE OF CXCR4 ANTAGONISTS | CXCR4, CXCR2, CXCR3 | CXCR4 1/4885MEN1 3707/4885CHRM2 1420/4885 |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | CCR2, CXCR4, CXCR2 | CXCR4 2/4885MEN1 4046/4885CHRM2 600/4885 |
| US-20150030561-A1 | Use of CXCR4 Antagonists | CXCR4, CXCR2, CXCR3 | CXCR4 1/4885MEN1 3707/4885CHRM2 1420/4885 |
| US-20060194776-A1 | Compositions and methods for treating tissue ischemia | CXCL12, CXCR4, PDGFA | CXCR4 2/4885MEN1 3672/4885CHRM2 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.